Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Positive 69.0%

Neg 0% Neu 0% Pos 69%

Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.